Prellis Biologics Generates 300 Human Antibodies That Bind SARS-CoV2 VirusAntibodies, Business, Coronavirus Vaccines, COVID-19 Infections, Immune System, Immunoglobulin G (IgG), Investments, Lymph Nodes, Product Pipeline, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus. Read more May 19, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/05/Prellis-Biologics-Generates-300-Human-Antibodies-That-Bind-SARS-CoV2-Virus-Business-Wire-5-19-20.jpg 323 450 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-05-19 13:00:262020-05-22 22:59:03Prellis Biologics Generates 300 Human Antibodies That Bind SARS-CoV2 Virus